Exchange: NASDAQ·Updated 07:57 PM EST

TXG News

News
all
press releases
10x Genomics (NASDAQ:TXG) Shares Climb 5.8% - Here's Why
10x Genomics (NASDAQ:TXG) Shares Climb 5.8% - What's Next...
MarketBeat
10x Genomics (NASDAQ:TXG) Shares Climb 5.8% - Here's Why
10x Genomics (NASDAQ:TXG) Shares Climb 5.8% - What's Next...
MarketBeat
More News
10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations 10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New CollaborationsPR NewswirePLEASANTON, Calif., Nov. 16, 2026 Collaborations with...
PR Newswire
Wall Street Zen upgraded 10x Genomics from a "hold" rating to a "buy" rating in a report on Saturday...
MarketBeat
TXG's Xenium platform is set to power a 500-patient breast cancer biomarker study, expanding its oncology research footprint and precision diagnostics potential.
Zacks
Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium PlatformPR...
PR Newswire
The latest round of trades touched multiple ARK ETFs, spanning artificial intelligence, semiconductors, biotechnology, defense and space-related companies.
Stocktwits
TXG launches Sentira Single Cell, a Claude-powered AI tool to simplify complex data analysis, accelerate research and unlock recurring revenue potential.
Zacks
10x Genomics raises its 2026 revenue outlook on strong Atera demand and spatial consumables growth, but production constraints and margin pressure remain challenges.
Zacks
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks

Advertisement|Remove ads.